Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1-(2-[18F]Fluoroethyl)-L-Tryptophan PET/CT Imaging in Human Cancers
NCT05556473Phase 1Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Sep 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]fluoroethyltryptophan in intracranial glioma, brain tumor, breast cancer and 2 more, sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoints: Percent difference in tracer uptake values between the tumor mass and the background and Correlation between tracer uptake values and tracer transport rates. Started Sep 2022; status: completed.
02
Drugs
[18F]fluoroethyltryptophan
03
Conditions
intracranial gliomabrain tumorbreast cancerNeuroendocrine Neoplasm (NEN)rectal cancer
Beyond the preview
Go deeper on NCT05556473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556473.